Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17628383,flow rate,"The elution was achieved isocratically with a mobile phase composed of 0.05% aqueous formic acid and acetonitrile (60:40, v/v) at a flow rate of 0.35 ml/min.","Development of a high performance liquid chromatography-tandem mass method for determination of bis(7)-tacrine, a promising anti-Alzheimer's dimer, in rat blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17628383/),[ml] / [min],0.35,11484,DB00382,Tacrine
,17628383,Retention times,"Retention times were 1.45 and 2.23 min for B7T and IS, respectively.","Development of a high performance liquid chromatography-tandem mass method for determination of bis(7)-tacrine, a promising anti-Alzheimer's dimer, in rat blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17628383/),min,1.45,11485,DB00382,Tacrine
,17628383,Retention times,"Retention times were 1.45 and 2.23 min for B7T and IS, respectively.","Development of a high performance liquid chromatography-tandem mass method for determination of bis(7)-tacrine, a promising anti-Alzheimer's dimer, in rat blood. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17628383/),min,2.23,11486,DB00382,Tacrine
,8430059,detection limit,Dialysis samples were analyzed using a microbore column chromatographic assay with a detection limit of 0.3 ng/ml.,"Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),[ng] / [ml],0.3,11713,DB00382,Tacrine
,8430059,t1/2,"Plasma pharmacokinetics followed a biexponential mode, with t1/2(dis.) = 8.4 +/- 2.7 min and t1/2(elim.) = 76.7 +/- 24.2 min for awake, freely moving rats.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,8.4,11714,DB00382,Tacrine
,8430059,t1/2,"Plasma pharmacokinetics followed a biexponential mode, with t1/2(dis.) = 8.4 +/- 2.7 min and t1/2(elim.) = 76.7 +/- 24.2 min for awake, freely moving rats.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,76.7,11715,DB00382,Tacrine
,8430059,t1/2,"In the brain of awake, freely moving rats t1/2(abs.) was 26.0 +/- 5.2 min and t1/2(elim.) was 99.1 +/- 17.7 min.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,26.0,11716,DB00382,Tacrine
,8430059,t1/2,"In the brain of awake, freely moving rats t1/2(abs.) was 26.0 +/- 5.2 min and t1/2(elim.) was 99.1 +/- 17.7 min.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,99.1,11717,DB00382,Tacrine
,8430059,t1/2,"For anesthetized rats, the t1/2(elim.) in blood was 154.8 +/- 46.8 min, while in the hippocampus t1/2(elim.) was 159.5 +/- 31.7 min.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,154.8,11718,DB00382,Tacrine
,8430059,t1/2,"For anesthetized rats, the t1/2(elim.) in blood was 154.8 +/- 46.8 min, while in the hippocampus t1/2(elim.) was 159.5 +/- 31.7 min.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),min,159.5,11719,DB00382,Tacrine
,8430059,binding,"The binding of THA in rat plasma was 56.2 +/- 5.0%, while the fraction bound to rat whole blood was 73.3 +/- 4.1% as determined by microdialysis and ultrafiltration.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),%,56.2,11720,DB00382,Tacrine
,8430059,fraction bound,"The binding of THA in rat plasma was 56.2 +/- 5.0%, while the fraction bound to rat whole blood was 73.3 +/- 4.1% as determined by microdialysis and ultrafiltration.","Distribution of tacrine across the blood-brain barrier in awake, freely moving rats using in vivo microdialysis sampling. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8430059/),%,73.3,11721,DB00382,Tacrine
,7480518,peak plasma concentrations,"Pharmacokinetic analysis following administration of 4 or 6 mg/kg velnacrine to three aged monkeys revealed peak plasma concentrations ranging from 27 to 166 ng/ml, 30-60 min after dosing.",Velnacrine maleate improves delayed matching performance by aged monkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7480518/),[ng] / [ml],27 to 166,40200,DB00382,Tacrine
,7656503,elimination half-life,"The elimination half-life of tacrine was short, 1.5 to 2.5 hours after single oral and intravenous doses and 2.9 to 3.6 hours after multiple oral doses.",Clinical pharmacokinetics of tacrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656503/),h,1.5 to 2.5,46704,DB00382,Tacrine
,7656503,elimination half-life,"The elimination half-life of tacrine was short, 1.5 to 2.5 hours after single oral and intravenous doses and 2.9 to 3.6 hours after multiple oral doses.",Clinical pharmacokinetics of tacrine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7656503/),h,2.9 to 3.6,46705,DB00382,Tacrine
,15179444,half-life,Its pharmacokinetic (PK) profile (half-life of 2 h) contrasts with the long lasting improvement in working memory (18 h) demonstrating that cognitive improvement extends beyond the lifetime of the compound.,"TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15179444/),h,2,53603,DB00382,Tacrine
,18059054,flow rate,"Chromatographic separation of B7T and IS was achieved in a C(18) reversed-phase HPLC column (150 x 2.1 mm i.d.) by isocratic elution with a mobile phase consisting of 0.05% formic acid in water and acetonitrile (1:1, v/v) at a flow rate of 0.35 mL/min.","Selective and sensitive determination of bis(7)-tacrine, a high erythrocyte binding acetylcholinesterase inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059054/),[ml] / [min],0.35,55007,DB00382,Tacrine
,18059054,detection limit,The detection limit of B7T in rat plasma was 1 ng/mL.,"Selective and sensitive determination of bis(7)-tacrine, a high erythrocyte binding acetylcholinesterase inhibitor, in rat plasma by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059054/),[ng] / [ml],1,55008,DB00382,Tacrine
,8973053,bioavailability,"The bioavailability of the oral formulation was low (9.9% to 36.4%), and the plasma half-life was not altered by route of drug delivery.",Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8973053/),%,9.9,71438,DB00382,Tacrine
,8973053,bioavailability,"The bioavailability of the oral formulation was low (9.9% to 36.4%), and the plasma half-life was not altered by route of drug delivery.",Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8973053/),%,36.4,71439,DB00382,Tacrine
,2039641,Plasma clearance (C1),"Plasma clearance (C1) was high and showed a twofold inter-individual variation, with a mean of 2.64 +/- 1.17 L/h.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[l] / [h],2.64,105731,DB00382,Tacrine
,2039641,Volume of distribution (Vd gamma),"Volume of distribution (Vd gamma) varied between 300 and 850 liters, with a mean of 477 +/- 185 liters.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),l,477,105732,DB00382,Tacrine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,2.1,105733,DB00382,Tacrine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,26,105734,DB00382,Tacrine
,2039641,plasma half-lives,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,133,105735,DB00382,Tacrine
,2039641,elimination,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,2.1,105736,DB00382,Tacrine
,2039641,elimination,"The plasma half-lives of rapid and slow distribution, and elimination were 2.1 +/- 0.7 minutes, 26 +/- 18 minutes, and 133 +/- 48 minutes, respectively.","Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),min,133,105737,DB00382,Tacrine
,2039641,Maximum plasma concentrations,Maximum plasma concentrations of 1-hydroxy-THA were 27 to 90 ng/ml in five patients; the concentration was below 1 ng/ml in two other patients.,"Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[ng] / [ml],27 to 90,105738,DB00382,Tacrine
below,2039641,Maximum plasma concentrations,Maximum plasma concentrations of 1-hydroxy-THA were 27 to 90 ng/ml in five patients; the concentration was below 1 ng/ml in two other patients.,"Pharmacokinetics and effects of 9-amino-1,2,3,4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2039641/),[ng] / [ml],1,105739,DB00382,Tacrine
,33852284,IC50,The assessment of the structure-activity relationships of such derivatives highlighted compound 1dC as a potent and selective acetylcholinesterase inhibitor with IC50 = 8 nM and 1aA as a potent butyrylcholinesterase inhibitor with IC50 = 15 nM.,Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33852284/),nM,8,116190,DB00382,Tacrine
,33852284,IC50,The assessment of the structure-activity relationships of such derivatives highlighted compound 1dC as a potent and selective acetylcholinesterase inhibitor with IC50 = 8 nM and 1aA as a potent butyrylcholinesterase inhibitor with IC50 = 15 nM.,Phenothiazine-Tacrine Heterodimers: Pursuing Multitarget Directed Approach in Alzheimer's Disease. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33852284/),nM,15,116191,DB00382,Tacrine
,18525282,Tmax,Lower Tmax values (60 min) after intranasal compared with intravenous administration (120 min) suggested selective nose-to-brain transport.,Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525282/),min,60,127524,DB00382,Tacrine
,18525282,Tmax,Lower Tmax values (60 min) after intranasal compared with intravenous administration (120 min) suggested selective nose-to-brain transport.,Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18525282/),min,120,127525,DB00382,Tacrine
,26561498,flow rate,"Chromatographic separation was achieved with 0.2% formic acid : acetonitrile (30 : 70, v/v) at a flow rate of 0.50 mL/min on an Atlantis dC18 column with a total run time of 3.0 min.",Highly Sensitive LC-MS-MS Method for the Determination of Tacrine in Rat Plasma: Application to Pharmacokinetic Studies in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561498/),[ml] / [min],0.50,128251,DB00382,Tacrine
,26561498,total run time,"Chromatographic separation was achieved with 0.2% formic acid : acetonitrile (30 : 70, v/v) at a flow rate of 0.50 mL/min on an Atlantis dC18 column with a total run time of 3.0 min.",Highly Sensitive LC-MS-MS Method for the Determination of Tacrine in Rat Plasma: Application to Pharmacokinetic Studies in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26561498/),min,3.0,128252,DB00382,Tacrine
,31642410,permeation flux,"The optimized nanoemulsion gel NEGT4 (droplet size 156.4 ±0.48 nm, with poly dispersity index 0.36 ±0.4, permeation flux 6.172±2.94 µg/cm2/h across rat skin) was prepared by spontaneous emulsification followed by sonication.","Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642410/),[μg] / [cm2·h],6.172,140511,DB00382,Tacrine
,31642410,shelf life,NEGT4 was found to be non-irritant and possessed a shelf life of 4.11 years.,"Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31642410/),years,4.11,140512,DB00382,Tacrine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1·mg·nM] / [h],0.06,140625,DB00382,Tacrine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.08-0.28,140626,DB00382,Tacrine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,0.75,140627,DB00382,Tacrine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),μM,5,140628,DB00382,Tacrine
,2723116,peak levels,"The mean peak levels ranged from 12.7 and 234.7 ng/ml after the 10 and 200 mg doses, respectively.","Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723116/),[ng] / [ml],12.7,141626,DB00382,Tacrine
,2723116,peak levels,"The mean peak levels ranged from 12.7 and 234.7 ng/ml after the 10 and 200 mg doses, respectively.","Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723116/),[ng] / [ml],234.7,141627,DB00382,Tacrine
,2723116,plasma half-life,The mean plasma half-life was about 2.0 hours and was not affected by dose.,"Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723116/),h,2.0,141628,DB00382,Tacrine
,15258105,K(i),Preincubation of CYP1A2 with tacrine and NADPH revealed a time-dependent inhibition of 7-ethoxyresorufin O-de-ethylation with a K(i) of 1.94 microM and a k(inact) of 0.091 min(-1).,Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258105/),μM,1.94,149781,DB00382,Tacrine
,15258105,k(inact),Preincubation of CYP1A2 with tacrine and NADPH revealed a time-dependent inhibition of 7-ethoxyresorufin O-de-ethylation with a K(i) of 1.94 microM and a k(inact) of 0.091 min(-1).,Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258105/),1/[min],0.091,149782,DB00382,Tacrine
,15258105,partition ratio,"Tacrine metabolism catalyzed by CYP1A was also carried out, and the partition ratio was estimated to be 22.",Inhibition of murine cytochrome P4501A by tacrine: in vitro studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15258105/),,22,149783,DB00382,Tacrine
,24709220,Tsol-gel,"The in situ gel demonstrated a liquid state with Newtonian fluid behavior under 20 °C, while it exhibited as non-flowing gel with pseudoplastic fluid behavior beyond its Tsol-gel of 28.5 °C.","Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24709220/),°c,28.5,155445,DB00382,Tacrine
,22975501,t(max),"In Part I, following a single- and multiple-dose, octahydrogenacridine succinate was rapidly absorbed with a median t(max) of 0.67 to 1.00 h, and was eliminated with a mean t1/2 of 2.27 to 2.98 h in all dose groups and did not appear to be dose dependent.","A single-center, randomized, open-label, dose-escalation study to evaluate the pharmacokinetics of tacrine analogue octahydrogenacridine succinate tablets in healthy Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22975501/),h,0.67 to 1.00,156300,DB00382,Tacrine
,22975501,t1/2,"In Part I, following a single- and multiple-dose, octahydrogenacridine succinate was rapidly absorbed with a median t(max) of 0.67 to 1.00 h, and was eliminated with a mean t1/2 of 2.27 to 2.98 h in all dose groups and did not appear to be dose dependent.","A single-center, randomized, open-label, dose-escalation study to evaluate the pharmacokinetics of tacrine analogue octahydrogenacridine succinate tablets in healthy Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22975501/),h,2.27 to 2.98,156301,DB00382,Tacrine
,15989517,terminal elimination half-life,"The compound has a terminal elimination half-life of 50 - 70 h in young volunteers; in elderly volunteers, the half-life of the compound is extended to over 100 h.","Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15989517/),h,50 - 70,168294,DB00382,Tacrine
over,15989517,half-life,"The compound has a terminal elimination half-life of 50 - 70 h in young volunteers; in elderly volunteers, the half-life of the compound is extended to over 100 h.","Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15989517/),h,100,168295,DB00382,Tacrine
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,8.5,169162,DB00382,Tacrine
,11261809,half-lives,"Following i.v. dosing, brain drug levels were 10-fold higher than those achieved in plasma, peaked within 5 min and rapidly declined with half-lives of 8.5 and 12.6 min, respectively.",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),min,12.6,169163,DB00382,Tacrine
>,11261809,half-life,"In contrast, a high (> 70%) and long-lasting inhibition of AChE was achieved (half-life > 8.25 h).",The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),h,8.25,169164,DB00382,Tacrine
,11261809,oral bioavailability,A comparison between the time-dependent plasma AChE inhibition achieved after similar oral and i.v. doses provided an estimate of oral bioavailability of 100%.,The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11261809/),%,100,169165,DB00382,Tacrine
,31257938,maximum plasma concentration,The maximum plasma concentration were attained at 18th min (tacrine; 38.20 ± 3.91 ng/ml and 7-MEOTA; 88.22 ± 15.19 ng/ml) after i.m. application in rats.,Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257938/),[ng] / [ml],38.20,174507,DB00382,Tacrine
,31257938,maximum plasma concentration,The maximum plasma concentration were attained at 18th min (tacrine; 38.20 ± 3.91 ng/ml and 7-MEOTA; 88.22 ± 15.19 ng/ml) after i.m. application in rats.,Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257938/),[ng] / [ml],88.22,174508,DB00382,Tacrine
,31257938,Kp (AUCbrain/AUCplasma),Although the brain profiles seem to be similar; tacrine achieved 19.34 ± 0.71 ng/ml in 27 min and 7-MEOTA 15.80 ± 1.13 ng/ml in 22 min; the tacrine Kp (AUCbrain/AUCplasma) fit 1.20 and was significantly higher than 7-MEOTA Kp 0.10.,Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257938/),,1.20,174509,DB00382,Tacrine
,31257938,Kp,Although the brain profiles seem to be similar; tacrine achieved 19.34 ± 0.71 ng/ml in 27 min and 7-MEOTA 15.80 ± 1.13 ng/ml in 22 min; the tacrine Kp (AUCbrain/AUCplasma) fit 1.20 and was significantly higher than 7-MEOTA Kp 0.10.,Tacrine and its 7-methoxy derivate; time-change concentration in plasma and brain tissue and basic toxicological profile in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31257938/),,0.10,174510,DB00382,Tacrine
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,335.2,179126,DB00382,Tacrine
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,184.2,179127,DB00382,Tacrine
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,199.1,179128,DB00382,Tacrine
,22715737,m/z,"Quantification was carried out on multiple reaction monitoring (MRM) of the transition m/z 395.2/324.2, m/z 335.2/184.2 and m/z 199.1/171.1 for brucine, strychnine and tacrine (internal standard), respectively.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),,171.1,179129,DB00382,Tacrine
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,78,179130,DB00382,Tacrine
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,102,179131,DB00382,Tacrine
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,95.2,179132,DB00382,Tacrine
,22715737,recoveries of extraction,The recoveries of extraction were 78.9% - 102.4% for brucine and 95.2% - 106.1% for strychnine.,[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),%,106,179133,DB00382,Tacrine
,22715737,C(max),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[μg] / [l],26.20,179134,DB00382,Tacrine
,22715737,C(max),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[μg] / [l],12.50,179135,DB00382,Tacrine
,22715737,AUC(0-infinity),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[h·μg] / [l],193.75,179136,DB00382,Tacrine
,22715737,AUC(0-infinity),"The C(max) were (26.20 +/- 5.81) and (12.50 +/- 3.00) microg x L(-1) while the AUC(0-infinity), were (193.75 +/- 39.43) and (98.25 +/- 28.54) microg x h x L(-1) of the two components.",[Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22715737/),[h·μg] / [l],98.25,179137,DB00382,Tacrine
,27030895,Extraction recovery,"Extraction recovery was in the range 63.5-72.1% for PC 48 and 70.5% for reserpine (internal standard, IS).",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),%,63.5-72.1,179540,DB00382,Tacrine
,27030895,Extraction recovery,"Extraction recovery was in the range 63.5-72.1% for PC 48 and 70.5% for reserpine (internal standard, IS).",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),%,70.5,179541,DB00382,Tacrine
,27030895,Cmax,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),[ng] / [ml],39.09,179542,DB00382,Tacrine
,27030895,Tmax,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),min,5.00,179543,DB00382,Tacrine
,27030895,AUC0-t,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),[min·ng] / [ml],23374,179544,DB00382,Tacrine
,27030895,t1/2,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),min,1065,179545,DB00382,Tacrine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,83,180839,DB00382,Tacrine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,97,180840,DB00382,Tacrine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,10,180841,DB00382,Tacrine
,24554118,bioavailabilities,"Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%).","Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24554118/),%,46,180842,DB00382,Tacrine
,19395215,C(max),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),[ng] / [ml],1.19,181537,DB00382,Tacrine
,19395215,T(max),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),h,0.77,181538,DB00382,Tacrine
,19395215,AUC(0-t),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),[h·ng] / [ml],3.42,181539,DB00382,Tacrine
,19395215,t(1/2),"Pharmacokinetic parameters for octahydroaminoacridine include C(max) 1.19+/-0.53 ng/ml, T(max) 0.77+/-0.17 h, AUC(0-t) 3.42+/-1.01 ng h/ml and t(1/2) 2.89+/-0.56 h.",Quantitation of the tacrine analogue octahydroaminoacridine in human plasma by liquid chromatography-tandem mass spectrometry. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395215/),h,2.89,181540,DB00382,Tacrine
,9209244,area under the plasma concentration versus time curve (AUC),"Fluvoxamine caused a significant increase in tacrine area under the plasma concentration versus time curve (AUC): arythmetic mean, 27 (95% confidence interval [CI], 19 to 38) ng.hr/ml versus 224 (95% CI, 166 to 302) ng. hr/ml.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[h·ng] / [ml],27,188359,DB00382,Tacrine
,9209244,area under the plasma concentration versus time curve (AUC),"Fluvoxamine caused a significant increase in tacrine area under the plasma concentration versus time curve (AUC): arythmetic mean, 27 (95% confidence interval [CI], 19 to 38) ng.hr/ml versus 224 (95% CI, 166 to 302) ng. hr/ml.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[h·ng] / [ml],224,188360,DB00382,Tacrine
,9209244,apparent oral clearance,"Fluvoxamine caused a decrease in the apparent oral clearance of tacrine from 1683 +/- 802 to 200 +/- 106 L/hr (mean +/- SD), which was explained by a decrease in its nonrenal clearance.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[l] / [h],1683,188361,DB00382,Tacrine
,9209244,apparent oral clearance,"Fluvoxamine caused a decrease in the apparent oral clearance of tacrine from 1683 +/- 802 to 200 +/- 106 L/hr (mean +/- SD), which was explained by a decrease in its nonrenal clearance.",Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9209244/),[l] / [h],200,188362,DB00382,Tacrine
,25558834,Chb,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),nM,100,195960,DB00382,Tacrine
,25558834,maximal Chb -to-maximal Cb ratio,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,2.3,195961,DB00382,Tacrine
,25558834,liver uptake,"Fluvoxamine and tacrine are known to exhibit relatively large F values despite having CLtot similar to or larger than hepatic blood flow, which may be because of the high liver uptake (almost 0.6) upon intravenous administration.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,0.6,195962,DB00382,Tacrine
,1800389,tmax,"The tmax was 4 hours and 1 h, t1/2 8.7 +/- 3.9 hours and 6.5 +/- 5.8 hours in case of p.o. and i.m. administration, respectively.",Pharmacokinetics and tolerance of 7-methoxytacrine following the single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800389/),h,4,197889,DB00382,Tacrine
,1800389,tmax,"The tmax was 4 hours and 1 h, t1/2 8.7 +/- 3.9 hours and 6.5 +/- 5.8 hours in case of p.o. and i.m. administration, respectively.",Pharmacokinetics and tolerance of 7-methoxytacrine following the single dose administration in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800389/),h,1,197890,DB00382,Tacrine
,1800389,t1/2,"The tmax was 4 hours and 1 h, t1/2 8.7 +/- 3.9 hours and 6.5 +/- 5.8 hours in case of p.o. and i.m. administration, respectively.",Pharmacokinetics and tolerance of 7-methoxytacrine following the single dose administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800389/),h,8.7,197891,DB00382,Tacrine
,1800389,t1/2,"The tmax was 4 hours and 1 h, t1/2 8.7 +/- 3.9 hours and 6.5 +/- 5.8 hours in case of p.o. and i.m. administration, respectively.",Pharmacokinetics and tolerance of 7-methoxytacrine following the single dose administration in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1800389/),h,6.5,197892,DB00382,Tacrine
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201245,DB00382,Tacrine
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201246,DB00382,Tacrine
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201247,DB00382,Tacrine
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201248,DB00382,Tacrine
,22196801,Extraction recoveries,Extraction recoveries of all analytes ranged from 82.1% to 93.2% in both rat plasma and brain tissue.,Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22196801/),%,82.1,218872,DB00382,Tacrine
,22196801,Extraction recoveries,Extraction recoveries of all analytes ranged from 82.1% to 93.2% in both rat plasma and brain tissue.,Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22196801/),%,93.2,218873,DB00382,Tacrine
,2598567,serum half-life,"The serum half-life was 1.59 +/- 0.15 hours (mean +/- SEM) after the 25 mg dose, 2.14 +/- 0.24 hours after the 50 mg dose, and 2.91 +/- 0.39 hours after continuous treatment.",Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598567/),h,1.59,221484,DB00382,Tacrine
,2598567,serum half-life,"The serum half-life was 1.59 +/- 0.15 hours (mean +/- SEM) after the 25 mg dose, 2.14 +/- 0.24 hours after the 50 mg dose, and 2.91 +/- 0.39 hours after continuous treatment.",Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598567/),h,2.14,221485,DB00382,Tacrine
,2598567,serum half-life,"The serum half-life was 1.59 +/- 0.15 hours (mean +/- SEM) after the 25 mg dose, 2.14 +/- 0.24 hours after the 50 mg dose, and 2.91 +/- 0.39 hours after continuous treatment.",Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598567/),h,2.91,221486,DB00382,Tacrine
above,2598567,clearance,"After intravenous administration, clearance was above 600 ml/min in both patients, and oral bioavailability was calculated at below 5%.",Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598567/),[ml] / [min],600,221487,DB00382,Tacrine
below,2598567,oral bioavailability,"After intravenous administration, clearance was above 600 ml/min in both patients, and oral bioavailability was calculated at below 5%.",Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598567/),%,5,221488,DB00382,Tacrine
,29966606,absolute bioavailability,"Oral administration only delivered trace amount of HLS-3 in systemic circulation with a high faecal recovery of 70.7%, whereas intranasal administration demonstrated an absolute bioavailability of 28.9% with urinary and faecal recoveries of 1.5% and 34.0%, respectively.",Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29966606/),%,28.9,228796,DB00382,Tacrine
,29966606,urinary,"Oral administration only delivered trace amount of HLS-3 in systemic circulation with a high faecal recovery of 70.7%, whereas intranasal administration demonstrated an absolute bioavailability of 28.9% with urinary and faecal recoveries of 1.5% and 34.0%, respectively.",Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29966606/),%,1.5,228797,DB00382,Tacrine
,29966606,faecal recoveries,"Oral administration only delivered trace amount of HLS-3 in systemic circulation with a high faecal recovery of 70.7%, whereas intranasal administration demonstrated an absolute bioavailability of 28.9% with urinary and faecal recoveries of 1.5% and 34.0%, respectively.",Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29966606/),%,1.5,228798,DB00382,Tacrine
,29966606,faecal recoveries,"Oral administration only delivered trace amount of HLS-3 in systemic circulation with a high faecal recovery of 70.7%, whereas intranasal administration demonstrated an absolute bioavailability of 28.9% with urinary and faecal recoveries of 1.5% and 34.0%, respectively.",Intranasal delivery of a novel acetylcholinesterase inhibitor HLS-3 for treatment of Alzheimer's disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29966606/),%,34.0,228799,DB00382,Tacrine
,10210906,half-life,"After this peak, the radioactivity remained quasi- constant until 60 minutes in all regions with a half-life varying from 2.44 hours in the thalamus to 3.42 hours in the cerebral cortex.",In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210906/),h,2.44,242868,DB00382,Tacrine
,10210906,half-life,"After this peak, the radioactivity remained quasi- constant until 60 minutes in all regions with a half-life varying from 2.44 hours in the thalamus to 3.42 hours in the cerebral cortex.",In vivo PET study of cerebral [11C] methyl- tetrahydroaminoacridine distribution and kinetics in healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10210906/),h,3.42,242869,DB00382,Tacrine
,8128833,elimination half-life,"The original compound in this class, physostigmine has an elimination half-life of 20-30 min.",Pharmacokinetic studies of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8128833/),min,20-30,246699,DB00382,Tacrine
,8128833,elimination half-lives,"Galanthamine, tacrine and the metabolite 1-hydroxytacrine (velnacrine) have longer elimination half-lives of 1.6-6 hours mainly due to a larger volume of distribution.",Pharmacokinetic studies of cholinesterase inhibitors. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8128833/),h,1.6-6,246700,DB00382,Tacrine
,2236461,maximum plasma concentrations (Cmax),"Mean maximum plasma concentrations (Cmax) were 5.1 ng/ml, 20.7 ng/ml, and 33.9 ng/ml following administration of 10 mg, 20 mg, and 30 mg doses, respectively.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [ml],5.1,249436,DB00382,Tacrine
,2236461,maximum plasma concentrations (Cmax),"Mean maximum plasma concentrations (Cmax) were 5.1 ng/ml, 20.7 ng/ml, and 33.9 ng/ml following administration of 10 mg, 20 mg, and 30 mg doses, respectively.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [ml],20.7,249437,DB00382,Tacrine
,2236461,maximum plasma concentrations (Cmax),"Mean maximum plasma concentrations (Cmax) were 5.1 ng/ml, 20.7 ng/ml, and 33.9 ng/ml following administration of 10 mg, 20 mg, and 30 mg doses, respectively.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [ml],33.9,249438,DB00382,Tacrine
,2236461,steady-state area under the curve (AUC),"Corresponding mean values for steady-state area under the curve (AUC) were 19.7 ng/ml, 82.9 ng/ml, and 139 ng/ml.hr.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [ml],19.7,249439,DB00382,Tacrine
,2236461,steady-state area under the curve (AUC),"Corresponding mean values for steady-state area under the curve (AUC) were 19.7 ng/ml, 82.9 ng/ml, and 139 ng/ml.hr.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [ml],82.9,249440,DB00382,Tacrine
,2236461,steady-state area under the curve (AUC),"Corresponding mean values for steady-state area under the curve (AUC) were 19.7 ng/ml, 82.9 ng/ml, and 139 ng/ml.hr.",Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),[ng] / [h·ml],139,249441,DB00382,Tacrine
,2236461,apparent elimination half-life,The apparent elimination half-life was approximately 3.4 hours for all dosing regimens.,Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2236461/),h,3.4,249442,DB00382,Tacrine
,2340845,Plasma clearance,Plasma clearance showed a threefold interindividual variation with a mean of 2.42 l.h-1.,"Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340845/),[l] / [h],2.42,253048,DB00382,Tacrine
,2340845,"Volume of distribution, V alpha","Volume of distribution, V alpha varied 100-680 l with a mean of 349 l.","Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340845/),l,349,253049,DB00382,Tacrine
,2340845,plasma half-lives of distribution,"The plasma half-lives of distribution and elimination were 1.8 and 98.2 min, respectively.","Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340845/),min,1.8,253050,DB00382,Tacrine
,2340845,elimination,"The plasma half-lives of distribution and elimination were 1.8 and 98.2 min, respectively.","Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340845/),min,98.2,253051,DB00382,Tacrine
,2340845,Oral bioavailability,Oral bioavailability showed large interindividual differences and ranged 6-36% in the four subjects studied.,"Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tetrahydroacridine, tacrine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2340845/),%,6-36,253052,DB00382,Tacrine
,24706520,flow rate,"Following a single liquid-liquid extraction with ethyl acetate, chromatographic separation was achieved at 25 °C on a BDS Hypersil C18 column with a mobile phase composed of 1% formic acid and methonal (30:70, v/v) at a flow rate of 0.2 mL/min.",Determination of tacrine-6-ferulic acid in rat plasma by LC-MS/MS and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706520/),[ml] / [min],0.2,267168,DB00382,Tacrine
,24706520,m,Quantification was achieved by monitoring the selected ions at m/z 474.2 → 298.1 for T6FA and m/z 432.2 → 199.0 for T3FA.,Determination of tacrine-6-ferulic acid in rat plasma by LC-MS/MS and its application to pharmacokinetics study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24706520/),,474.2,267169,DB00382,Tacrine
,2592587,peak plasma levels,"Administration of velnacrine with food resulted in slightly lower peak plasma levels of unconjugated velnacrine, (175 vs 213 ng/ml) and delayed times-to-peak plasma levels, (2.5 vs 1.5 h) without affecting the AUCs and the t 1/2 of the drug.",The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2592587/),[ng] / [ml],175,270880,DB00382,Tacrine
,2592587,peak plasma levels,"Administration of velnacrine with food resulted in slightly lower peak plasma levels of unconjugated velnacrine, (175 vs 213 ng/ml) and delayed times-to-peak plasma levels, (2.5 vs 1.5 h) without affecting the AUCs and the t 1/2 of the drug.",The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2592587/),[ng] / [ml],213,270881,DB00382,Tacrine
,2592587,times-to-peak plasma levels,"Administration of velnacrine with food resulted in slightly lower peak plasma levels of unconjugated velnacrine, (175 vs 213 ng/ml) and delayed times-to-peak plasma levels, (2.5 vs 1.5 h) without affecting the AUCs and the t 1/2 of the drug.",The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2592587/),h,2.5,270882,DB00382,Tacrine
,2592587,times-to-peak plasma levels,"Administration of velnacrine with food resulted in slightly lower peak plasma levels of unconjugated velnacrine, (175 vs 213 ng/ml) and delayed times-to-peak plasma levels, (2.5 vs 1.5 h) without affecting the AUCs and the t 1/2 of the drug.",The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2592587/),h,1.5,270883,DB00382,Tacrine
,8866685,steady-state concentration,A mean average steady-state concentration in plasma ranging from 1.1 to 30 ng/ml was obtained with doses ranging from 40 to 160 mg of tacrine daily.,Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866685/),[ng] / [ml],1.1 to 30,272007,DB00382,Tacrine
,8866685,maximal plasma concentration,During treatment with 80 mg daily a maximal plasma concentration of tacrine (8.7 +/- 0.6 ng/ml) was obtained 1.3 +/- 0.2 h after intake of the morning dose.,Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866685/),[ng] / [ml],8.7,272008,DB00382,Tacrine
,8866685,ratio CSF/plasma concentration,The tacrine concentration in CSF was measured in each patient on 1-3 occasions during the treatment and the ratio CSF/plasma concentration was estimated to be 0.47 +/- 0.09 (n = 11).,Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866685/),,0.47,272009,DB00382,Tacrine
